US-based personalised orthopaedic implants provider Restor3d has secured $38m financing from existing and new private investors, including Summers Value Partners.
Restor3d intends to use the funding to support the expansion and the introduction of four advanced 3D printed product lines in 2025 and 2026.
The company is nearing positive operating cash flow, enabling continued reinvestment in innovation and expansion while maintaining financial stability.
The capital will advance the commercialisation of four new fully 3D printed product lines, each designed to enhance surgical precision and patient outcomes.
Restor3d’s Veritas Reverse Total Shoulder System features a single-tray instrument system for patient-specific implants.
Pending US Food and Drug Administration (FDA) 510(k) approval, the system optimises joint centre rotation and fixation with TIDAL Technology for improved bone integration.
The iTotal Identity 3DP Porous Cementless Total Knee, recently cleared by the FDA, offers a fully cementless, patient-specific knee system for optimal coverage and alignment.
The Kinos Modular Stem Total Ankle System, which received FDA clearance last year, is designed for an anterior approach, providing surgical flexibility and personalised fit.
The Velora 3DP Porous Acetabular System, pending FDA approval, incorporates TIDAL Technology for enhanced osseointegration and stability in hip arthroplasty.
Building on the 3D printing technology, Restor3d aims to reshape the future of orthopaedics through improved surgical precision, patient outcomes, and procedural efficiency.
Restor3d CEO and co-founder Kurt Jacobus said: “From the beginning, our mission at restor3d has been to transform orthopaedic care through personalised, data-driven solutions.
“By leveraging advanced 3D printing and AI-driven design, we are restoring mobility and improving lives, whether its helping patients return to work, get back on the golf course, or simply walk without pain.
“This approach has allowed us to expand market share efficiently, rapidly enter new segments, and drive strong year-over-year growth.
“This funding allows us to further scale our technology, expand access to truly personalised care, and continue setting new standards in orthopaedic treatment. We are redefining what’s possible in orthopaedics to better serve our surgeons and patients.”
